Abstract
differences in cancer cells and their interactions with a complex microenvironment. This 23 heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-24 specific genomic or transcriptomic profiles. Subtyping can lead to biomarker identification for 25 personalized diagnosis and therapy, but stratification alone does not explain the origins of 26 tumor heterogeneity. Heterogeneity has traditionally been thought to arise from distinct 27 mutations/aberrations in "driver" oncogenes. However, certain subtypes appear to be the result 28 of adaptation to the disrupted microenvironment caused by abnormal tumor vasculature 29 triggering metabolic switches. Moreover, heterogeneity persists despite the predominance of 30 single oncogenic driver mutations, perhaps due to second metabolic or genetic "hits". In certain 31 cancer types, existing subtypes have metabolic and transcriptomic phenotypes that are 32 reminiscent of normal differentiated cells, whereas others reflect the phenotypes of stem or 33 mesenchymal cells. The cell-of-origin may, therefore, play a role in tumor heterogeneity. In 34 this mini-review, we focus on how cancer cell-specific heterogeneity is driven by different (1-6). However, the true extent of intra-tumoral molecular heterogeneity is only just being 47 elucidated, in part due to the recent exploitation of high-throughput genomic analyses of 48 multiple biopsies from individual tumors or by the isolation and analysis of single cells (7). In 49 general, heterogeneity in cancer cells can manifest itself in two key ways: first, by major 50 genetic events such as somatic copy number aberrations (SCNAs) and mutations; and second, Figure 1B -left panel) . 237
238
In contrast, MLP subtype tumors are poorly differentiated and non-functional (i.e. no hormones 239 can be detected in the blood) and are associated with liver metastases and high tumor grades. 240
This subtype possesses a typical pancreatic stem/precursor cells or immature β celltranscriptional signature and expresses genes associated with fibroblasts, stroma, stem cells, 242 and hypoxia (see Figure 1B) . 243
244
The Cell-of-Origin/Phenotype of Colorectal Tumors We discovered five clinically pertinent 245 colorectal cancer (CRC) subtypes by mRNA profiling of 1,290 tumors ("stem-like", "transit 246 amplifying" (TA), "enterocyte", "goblet-like", and "inflammatory" subtypes) (4). 247
Comparisons with known colon-crypt cell type gene signatures revealed likely cell-of-248 origin/phenotype candidates (see Figure 1B) . For example, the goblet-like and enterocyte 249 subtype signatures were associated with those of the normal goblet and enterocyte cells (colon 250 crypt top), while the stem-like subtype was associated with the crypt base, implicating these 251 sites as the putative cell-of-origins for these subtypes. The stem-like subtype (with low 252 differentiation marker expression) showed high stem cell, myoepithelial/mesenchymal and 253 stromal gene expression. 254
255
Although these profiles were subsequently independently confirmed (35), other studies have 256 concluded that CRCs can be divided into between three and six subtypes (36). Reconciliation 257 of these subtypes has revealed that these classifications were in fact in broad agreement for 258 four subtypes, with the remainder being further subdivisions of these "consensus molecular 259 subtypes" (CMS) (36). One of these four CMS subtypes, which maps to our differentiated 260 goblet-like subtype, was dubbed the "metabolic" (or CMS3) subtype (36) due to its enrichmentfor several metabolic gene signatures, and was associated with high KRAS mutation frequency, 262 whose influence on metabolism is discussed above (24, 25) . 
Concluding Remarks

289
Overall, there appears to be at least three broad divisions of the origins of tumor heterogeneity 290 and subtypes based on metabolic, genetic and/or molecular changes. The first are subtypes with 291 initial tumorigenic driver genetic or metabolic aberration(s) that give rise to different tumor 292 subtypes ( Figure 1A -left and right panels) . Nonetheless, an initial aberration as a first hit 293 in their normal counterparts is probably followed by the gain of additional secondary genetic 294 or metabolic aberration(s) that further drive progression and affect patient prognosis ( Figure  295 1A -left panel). In the second main group of cancers, cell-of-origin determines the subtypes, 296 with certain differentiated subtypes maintaining the transcriptomic and other important 297 characteristics of their well-differentiated normal counterparts (38) (e.g. pyruvate cycling (5)) 298 and being addicted to more normal cellular energy metabolism. Most of these subtypes have 299 favorable prognosis ( Figure 1B -left panel) . Others, probably originating from 300 stem/precursor cells, are likely to shift their energy metabolism toward glycolysis and othermalignant metabolisms, and have a poorer prognosis ( Figure 1B -right panel) . Finally, the 302 
